StonklyGainz

OpGen Long - Possible FDA approval soon

做多
StonklyGainz 已更新   
NASDAQ:OPGN   OpGen, Inc.
OpGen has gone through a complete accumulation cycle in anticipation of FDA approval for their AMR gene panel. During the last few days of broad market pull back, we see above average volume the downside holding support at $2.80 - $2.90. RSI on the 1HR is approaching oversold. SP has fallen through 50EMA we could possibly see a correction back to uptrend support. 1HR resistance around $3.20 $3.50 $4.00 $4.50 $4.80

Recent Corporate Overview published on 2/16/21

Google - "wyckoff accumulation schematic 1" for more information on accumulation cycle
交易开始:
Current average $2.937

Point and Figure chart has bullish price objective of $6.25
评论:
Recent news
3/1 - receives regulatory approval of the Curetis Unyvero System as an in vitro diagnostics ((IVD)) instrument system in China.
3/2 - Analysts raise price target to $7.00
评论:
Posted update in comments by accident. Also to add, 3.1M new warrants issued to the previous holder at an exercise price of $3.56
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。